Alpha-GPC vs Phosphatidylserine
Two cholinergic/phospholipid nootropics with real but dated human trial data — one from dementia trials, the other from a form of the ingredient no longer actually sold.
Short answer
Alpha-GPC and phosphatidylserine are both over-the-counter supplements with human trial data, so the choice comes down to your goal. Alpha-GPC suits someone focused on cognitive enhancement, nootropic use and dementia (as an adjunct), while phosphatidylserine is aimed at cognitive decline, memory and stress/cortisol.
Alpha-GPC
Choline alfoscerate, choline alphoscerate, L-alpha-glycerylphosphorylcholine
Its strongest human evidence is a randomized dementia trial and an add-on Alzheimer's trial (ASCOMALVA) — not the healthy 'nootropic' population that drives most sales. A 2021 observational analysis also flagged an association with increased 10-year stroke risk that remains unresolved, an open question for anyone with cardiovascular risk factors.
Full Alpha-GPC evidence reviewPhosphatidylserine
PS
The strongest human data comes from older trials using bovine-brain-derived PS, which is no longer sold (BSE concerns); the soy-derived PS on shelves today is chemically different and has a thinner, weaker trial record of its own.
Full Phosphatidylserine evidence reviewAlpha-GPC vs Phosphatidylserine: head to head
- FDA status / approved use
Alpha-GPC
Sold as a supplement; used as a prescription agent for cognitive disorders in several European countriesPhosphatidylserine
Sold as a supplement; FDA allows only a qualified health claim with a disclaimer- Marketed for
Alpha-GPC
Cognitive enhancement / nootropic use, dementia adjunctPhosphatidylserine
Cognitive decline, memory, stress/cortisol- Outcome areas
Alpha-GPC
Cognitive function / memory; CardiovascularPhosphatidylserine
Cognitive function / memory; Mood / anxiety / stress- Evidence grade
Alpha-GPC
Clinical dataPhosphatidylserine
Clinical data- How it works
Alpha-GPC
Supplies choline for making acetylcholine, a neurotransmitter tied to attention and memoryPhosphatidylserine
Membrane phospholipid concentrated in neurons that supports neurotransmitter release- Route and dosing
Alpha-GPC
Supplement taken daily; one strength trial used 600 mg/dayPhosphatidylserine
Oral supplement; trials used 300 or 600 mg daily- Headline human result
Alpha-GPC
Cognitive improvement on standardized scales vs placebo in a 2003 randomized trial in mild-to-moderate Alzheimer's dementiaPhosphatidylserine
No memory benefit vs placebo with soy-derived PS at 300 or 600 mg daily in a 12-week RCT of 120 older adults- Strongest evidence
Alpha-GPC
De Jesus Moreno Moreno 2003 RCT, Clin TherAlpha-GPC evidence reviewPubMed 12637119Phosphatidylserine
Bovine-PS cognitive decline RCT, Aging Clin Exp Res 1993Phosphatidylserine evidence reviewPubMed 8323999- Key safety signal
Alpha-GPC
Linked to higher 10-year stroke risk in a large 2021 observational analysis; causation not establishedPhosphatidylserine
Generally well tolerated; mild gastrointestinal upset is the most common complaint- How it is obtained
Alpha-GPC
Over the counter as a dietary supplementPhosphatidylserine
Over the counter as a dietary supplement
| Alpha-GPC | Phosphatidylserine | |
|---|---|---|
| FDA status / approved use | Sold as a supplement; used as a prescription agent for cognitive disorders in several European countries | Sold as a supplement; FDA allows only a qualified health claim with a disclaimer |
| Marketed for | Cognitive enhancement / nootropic use, dementia adjunct | Cognitive decline, memory, stress/cortisol |
| Outcome areas | Cognitive function / memory; Cardiovascular | Cognitive function / memory; Mood / anxiety / stress |
| Evidence grade | Clinical data | Clinical data |
| How it works | Supplies choline for making acetylcholine, a neurotransmitter tied to attention and memory | Membrane phospholipid concentrated in neurons that supports neurotransmitter release |
| Route and dosing | Supplement taken daily; one strength trial used 600 mg/day | Oral supplement; trials used 300 or 600 mg daily |
| Headline human result | Cognitive improvement on standardized scales vs placebo in a 2003 randomized trial in mild-to-moderate Alzheimer's dementia | No memory benefit vs placebo with soy-derived PS at 300 or 600 mg daily in a 12-week RCT of 120 older adults |
| Strongest evidence | De Jesus Moreno Moreno 2003 RCT, Clin TherAlpha-GPC evidence reviewPubMed 12637119 | Bovine-PS cognitive decline RCT, Aging Clin Exp Res 1993Phosphatidylserine evidence reviewPubMed 8323999 |
| Key safety signal | Linked to higher 10-year stroke risk in a large 2021 observational analysis; causation not established | Generally well tolerated; mild gastrointestinal upset is the most common complaint |
| How it is obtained | Over the counter as a dietary supplement | Over the counter as a dietary supplement |
marks a row where the two differ. “Not established” marks a cell the available evidence does not answer. Evidence grades come from our evidence matrix, which grades each molecule on the human data for the use it is marketed for.
- Clinical data:
- Tested in humans — but investigational, discontinued, or proven only on a surrogate marker (not the marketed outcome).
Our verdict
Alpha-GPC's strongest evidence is a randomized Alzheimer's trial and an add-on benefit in treated dementia patients — real, but in a population unlike the healthy users who buy it, plus an unresolved 2021 stroke-risk signal. Phosphatidylserine's strongest data used bovine-brain-derived PS, discontinued after BSE concerns; the soy-derived PS sold today is a chemically different molecule with its own, thinner trial record. Both are cases where the product on the shelf isn't quite the product that was studied.
Alpha-GPC fits if
You want the more actively marketed option, and you don't have elevated cardiovascular risk factors given alpha-GPC's unresolved stroke signal.
Phosphatidylserine fits if
You want to avoid alpha-GPC's stroke-risk question, understanding that today's soy-PS has thinner evidence than the original bovine-PS trials.
Alpha-GPC vs Phosphatidylserine: common questions
- Is either alpha-GPC or phosphatidylserine FDA-approved?
- No. Alpha-GPC is sold as a supplement; used as a prescription agent for cognitive disorders in several European countries. Phosphatidylserine is sold as a supplement; FDA allows only a qualified health claim with a disclaimer.
- Which has stronger human evidence, alpha-GPC or phosphatidylserine?
- Neither clearly. Both have human clinical data. The key source for alpha-GPC is De Jesus Moreno Moreno 2003 RCT, Clin Ther; for phosphatidylserine, it is Bovine-PS cognitive decline RCT, Aging Clin Exp Res 1993.
- What are the main safety concerns with alpha-GPC and phosphatidylserine?
- Alpha-GPC is linked to higher 10-year stroke risk in a large 2021 observational analysis; causation not established. Phosphatidylserine is generally well tolerated; mild gastrointestinal upset is the most common complaint.
Key studies behind each
Alpha-GPC
- De Jesus Moreno Moreno M (2003). Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alfoscerate: a multicenter, double-blind, randomized, placebo-controlled trial. Clinical Therapeutics. PubMed 12637119
- Carotenuto A, et al. (2017). The Effect of the Association between Donepezil and Choline Alphoscerate on Behavioral Disturbances in Alzheimer's Disease: Interim Results of the ASCOMALVA Trial. Journal of Alzheimer's Disease. PubMed 28035924
- Rea R, et al. (2015). Apathy Treatment in Alzheimer's Disease: Interim Results of the ASCOMALVA Trial. Journal of Alzheimer's Disease. PubMed 26402001
- Bellar D, et al. (2015). The effect of 6 days of alpha glycerylphosphorylcholine on isometric strength. Journal of the International Society of Sports Nutrition. PubMed 26582972
Phosphatidylserine
- Cenacchi T, Bertoldin T, Farina C, et al. (1993). Cognitive decline in the elderly: a double-blind, placebo-controlled multicenter study on efficacy of phosphatidylserine administration. Aging (Milano). PubMed 8323999
- Jorissen BL, Brouns F, Van Boxtel MP, et al. (2001). The influence of soy-derived phosphatidylserine on cognition in age-associated memory impairment. Nutritional Neuroscience. PubMed 11842880
- Monteleone P, Maj M, Beinat L, et al. (1992). Blunting by chronic phosphatidylserine administration of the stress-induced activation of the hypothalamo-pituitary-adrenal axis in healthy men. European Journal of Clinical Pharmacology. PubMed 1325348
- Parker AG, Gordon J, Thornton A, et al. (2011). The effects of IQPLUS Focus on cognitive function, mood and endocrine response before and following acute exercise. Journal of the International Society of Sports Nutrition. PubMed 22017963
The full evidence reviews
- Alpha-GPC: What the Evidence Actually Shows
A cholinergic precursor with real dementia-trial data, weak ergogenic studies, and an unresolved 2021 stroke-risk signal.
Updated August 2026
- Phosphatidylserine: Evidence for Memory, Cortisol, and Cognitive Health
A membrane phospholipid with real biology, older positive cognition data on a form you can no longer buy, and a weaker case for the soy-derived version sold today.
Updated August 2026